Kansas City, KS. – (June 2016) KCAS Bioanalytical and Biomarker Services, a leading functional
service contract research organization (CRO) has welcomed John Bucksath, as CEO.
“We believe the addition of John Bucksath to an already strong team at KCAS will help the company
continue to grow as a leader in the CRO industry. John’s prior experience at ABC Laboratories has shown
his values closely align with the values of KCAS. We look forward to expanding relationships with our
customers and partners, and we are excited about the future of KCAS under John’s leadership.” states
Brian Lueger, board member at KCAS.
Mr. Bucksath is a seasoned industry executive with more than 26 years in drug development, 13 of
which in senior management roles, focused on strategic marketing and sales planning, GLP and GMP
quality systems design, operations process improvement and laboratory design. Most recently, he was
president and CEO of a regional CRO. He holds an MBA from Washington University and a BA in Biology
with a Minor in Chemistry from Central Methodist University.
“I am excited to join the KCAS team and help strengthen its position as a leader in bioanalytical and
biomarker services. Our focus will begin by expanding our operations and growing partner relationships.
We have enormous potential to broaden our presence in the market, while continuing to concentrate
on what KCAS’ clients love most about us – our commitment to consistent quality, communication, and
skill in method development and validation.” states John Bucksath, new CEO of KCAS.
KCAS Bioanalytical & Biomarker Services is a contract laboratory with 36+ years of bioanalytical
expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity,
and biomarker analysis operating a variety of equipment platforms to service a wide range of
therapeutic areas. KCAS’ team leverages a highly scientific staff with an average tenure of 14 years at
the company to provide clients of all sizes with expertise in robust assay development, validation, and
sample analysis under non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies.
Our teams have developed and validated more than 5,500 bioanalytical assays and have undergone 15
FDA inspections. Recently KCAS registered for Clinical Laboratory Improvement Amendments (CLIA)
certification. Learn more at: www.kcasbio.com